Novel hydrogel adjuvant based on quaternized chitosan for H5N1 split vaccine

Wu, Jie; Wang, Yueqi; Fan, Qingze; Wu, Youbin; Ma, Guanghui

doi:10.1016/j.jconrel.2015.05.084

Cited by 6 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biocompatibility test showed that crosslinking hydrogel was non-cytotoxic. Wu et al 134 utilized the ion crosslinking method to prepare a quaternary ammonium chitosan material with thermal effect, which could be changed from colloidal sol state to gel state. Crosslinking can reduce the adsorption capacity of chitosan, but the loss of this ability is a prerequisite for ensuring the stability of polymers.…”

Section: Research Progress On Modification Methods Of Chitosan Dressingmentioning

confidence: 99%

Application status and technical analysis of chitosan-based medical dressings: a review

Zhang

et al. 2020

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Research Progress On Modification Methods Of Chitosan Dressingmentioning

confidence: 99%

Application status and technical analysis of chitosan-based medical dressings: a review

Zhang

et al. 2020

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…At body temperature, the intranasally-administered system showed sol-gel transition, leading to prolongation of the antigen residence time in the nasal cavity. The enhanced humoral and cellular immune responses and the increased antigen-specific mucosal IgA titres elicited by the adjuvant-free H5N1 hydrogel vaccine, when compared to the naked H5N1 split antigen and MF59 adjuvant/antigen complex, were all attributed to prolonged release of antigen and disorganisation of ZO-1 protein of the nasal epithelium resulting in enhanced transepithelial transport of the antigen [262,263]. Moreover, this HTCC/GP thermosensitive hydrogel vaccine delivery system was previously used for IN vaccination with the adenovirus-based Zaire Ebola virus glycoprotein antigen (Ad-GPZ) [264].…”

Section: Polymeric Hydrogelsmentioning

confidence: 99%

Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application

et al. 2021

View full text Add to dashboard Cite

Viral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strategy to control such viral infections, with the successful and recently accelerated development of different types of vaccines, thanks to the advanced biotechnological techniques involved in the upstream and downstream processing of these products. However, there is still much work to be done for the improvement of efficacy and safety when it comes to the choice of delivery systems, formulations, dosage form and route of administration, which are not only crucial for immunisation effectiveness, but also for vaccine stability, dose frequency, patient convenience and logistics for mass immunisation. In this review, we discuss the main vaccine delivery systems and associated challenges, as well as the recent success in developing nanomaterials-based and advanced delivery systems to tackle these challenges. Manufacturing and regulatory requirements for the development of these systems for successful clinical and marketing authorisation were also considered. Here, we comprehensively review nanovaccines from development to clinical application, which will be relevant to vaccine developers, regulators, and clinicians.

show abstract

“…Pursuing this, we developed a method for embedding the CNVs into a thermosensitive hydrogel as an antigen depot at the injection site. [52,53] Considering biocompatibility and almost nonadjuvant property (Figure S3, Supporting Information), we chose chitosan glutamate (CG) to prepare a thermosensitive hydrogel through physical crosslinking with 𝛼, 𝛽-glycerophosphate, which existed as a solution with low viscosity at room temperature (RT) but transited into a gel at 37 °C (Figure S4, Supporting Information). We anticipated that we could gently mix CNVs with the liquid form of the hydrogel and then the body temperature of mice would facilitate formation of a gel (postvaccination), thereby embedding CNVs in its porous network (Figure 2a We mixed the CNVs and the hydrogel solution at room temperature in a 3:7 volume ratio, and noted that the inclusion of CNVs did not greatly affect the rheological behavior of hydrogel, causing only a slight increase for the gelation time (Figure 2b; Figure S4, Supporting Information).…”

Section: Recruitment Behavior Of Gel-confined Cnvs In Vivomentioning

confidence: 99%

Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy

Wang

Tong

et al. 2020

Advanced Science

Self Cite

View full text Add to dashboard Cite

Nanovaccines have attracted booming interests in vaccinology studies, but the profound impacts of their delivery mode on immune response remain unrealized. Herein, immunostimulatory CpG-modified tumor-derived nanovesicles (CNVs) are used as a nanovaccine testbed to initially evaluate the impacts of three distinct delivery modes, including mono-pulse CNVs, staggered-pulse CNVs, and gel-confined CNVs. Fundamentally, delivery mode has enormous impacts on the immunomodulatory effects, altering the spatiotemporal distribution of nanovaccine residence and dendritic cell-T cell interaction in lymph nodes, and finally affecting subsequent T cell-mediated immune performance. As a result, the gel-confined delivery mode offers the best therapeutic performance in multiple tumor models. When extending evaluation to examine how the various delivery modes impact the performance of liposome-based nanovaccines, similar trends in intralymph node distribution and antitumor effect are observed. This work provides a strong empirical foundation that nanovaccine researchers should position delivery mode near the top of their considerations for the experimental design, which should speed up nanovaccine development and facilitate efficient selection of appropriate delivery modes in the clinic.

show abstract

Novel hydrogel adjuvant based on quaternized chitosan for H5N1 split vaccine

Cited by 6 publications

References 2 publications

Application status and technical analysis of chitosan-based medical dressings: a review

Application status and technical analysis of chitosan-based medical dressings: a review

Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application

Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy

Contact Info

Product

Resources

About